Form 4: AbbVie Director Robert J. Alpern Reports Changes in Beneficial Ownership

Director Robert J. Alpern reports acquisition of stock equivalent units in AbbVie through director fees and dividend reinvestment.

Summary

• Robert J. Alpern, a director of AbbVie Inc., filed a Form 4 on January 3, 2025, reporting changes in beneficial ownership of AbbVie securities.
• The report indicates that Alpern acquired 42 stock equivalent units on December 31, 2024, at a price of $177.7, through director fees credited to stock equivalent unit accounts under grantor trusts.
• These stock equivalent units earn the same return as if the fees were invested in AbbVie stock and will be paid in cash generally at age 65 or upon retirement from AbbVie's board.
• The balance of stock equivalent units beneficially owned following the reported transaction is 9,788, which includes units acquired pursuant to a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The director is increasing their holdings, which can be seen as a positive sign, but it's also part of a standard compensation package.

Positives

• The director's continued investment in stock equivalent units demonstrates confidence in AbbVie's future performance.

Future Outlook

The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board.

Industry Context

Directors often receive compensation in the form of stock or stock equivalent units to align their interests with those of shareholders. This Form 4 filing reflects a common practice in corporate governance.

Comparison to Industry Standards

• Director compensation packages often include stock options, restricted stock units, or stock equivalent units to incentivize long-term value creation.
• Companies like Johnson & Johnson and Pfizer also utilize similar compensation structures for their directors.
• The specific terms of these arrangements, such as vesting schedules and payout conditions, can vary widely across companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals director confidence.

Key Dates